Ritter Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• RP-G28 · Gastroenterology / Metabolic Disease
  RP-G28 is a non-systemic oral therapeutic that modulates the gut microbiome to improve metabolic and immune function.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ritter Pharmaceuticals, Inc. portfolio CI brief
• Ritter Pharmaceuticals, Inc. pipeline updates RSS